1. Research progress on hydrogel-based drug therapy in melanoma immunotherapy
   Wei He et al, 2024, BMB Reports CrossRef
2. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
   Rima Hajjo et al, 2024, Expert Opinion on Therapeutic Patents CrossRef
3. Exogenous Hydrogen Sulfide Induces A375 Melanoma Cell Apoptosis Through Overactivation of the Unfolded Protein Response
   Weiyuan Ma et al, 2023, Clinical, Cosmetic and Investigational Dermatology CrossRef
4. Dendritic Cell-Derived Exosomes Driven Drug Co-Delivery Biomimetic Nanosystem for Effective Combination of Malignant Melanoma Immunotherapy and Gene Therapy
   Jiecheng Lin et al, 2023, Drug Design, Development and Therapy CrossRef
5. PARVB promotes malignant melanoma progression and is enhanced by hypoxic conditions
   Ting Wang et al, 2024, Translational Oncology CrossRef
6. The Assessment of Anti-Melanoma Potential of Tigecycline—Cellular and Molecular Studies of Cell Proliferation, Apoptosis and Autophagy on Amelanotic and Melanotic Melanoma Cells
   Jakub Rok et al, 2023, Cells CrossRef
7. Nidogen-2 (NID2) is a Key Factor in Collagen Causing Poor Response to Immunotherapy in Melanoma
   Yan Sha et al, 2023, Pharmacogenomics and Personalized Medicine CrossRef
8. Outcomes of Patients with Metastatic Melanoma—A Single-Institution Retrospective Analysis
   Lidia Szatkowska et al, 2022, Cancers CrossRef
9. Current Controversies in Melanoma Treatment
   Claire Temple-Oberle et al, 2023, Plastic & Reconstructive Surgery CrossRef
10. Antitumor Activities of Interleukin-12 in Melanoma
    Wei Gao et al, 2022, Cancers CrossRef
11. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy
    Paulina Stachyra-Strawa et al, 2024, Genes CrossRef
12. Immunotherapy and delivery systems for melanoma
    Hui Liu et al, 2024, Human Vaccines & Immunotherapeutics CrossRef
13. Ruthenium(II) complex with 2-mercaptothiazoline ligand induces selective cytotoxicity involving DNA damage and apoptosis in melanoma cells
    Matheus Reis Santos de Melo et al, 2024, JBIC Journal of Biological Inorganic Chemistry CrossRef
14. Managing Metastatic Melanoma in 2022: A Clinical Review
    Benjamin Switzer et al, 2022, JCO Oncology Practice CrossRef
15. C118P exerted potent anti-tumor effects against melanoma with induction of G2/M arrest via inhibiting the expression of BUB1B
    Kun Ren et al, 2022, Journal of Dermatological Science CrossRef